Allos Therapeutics to Report Second Quarter 2009 Results on August 4, 2009
22 Juillet 2009 - 2:00PM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics, today announced that Company
management will provide a corporate update and review of the second
quarter 2009 results via webcast and conference call on Tuesday,
August 4, 2009, at 4:30 p.m. ET.
The webcast of this call will be available from the homepage and
the investors/media section of the Company's Web site,
www.allos.com. Alternatively, callers may participate in the
conference call by dialing 888-549-7880 (domestic) or 480-629-9869
(international). Participants should reference the Allos
Therapeutics conference call. Webcast and telephone replays of the
conference call will be available approximately two hours after the
completion of the call through Friday, August 14, 2009. To access
the replay, callers should dial 1-800-406-7325 (domestic) or
303-590-3030 (international) and use passcode 4117858#.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics. The Company�s product
candidate, pralatrexate, is a selective antifolate designed to
accumulate preferentially in cancer cells. The Company recently
announced that the U.S. Food and Drug Administration (FDA) accepted
its New Drug Application (NDA) for pralatrexate for patients with
relapsed or refractory peripheral T-cell lymphoma for priority
review and established a Prescription Drug User Fee Act date of
September 24, 2009 for a decision regarding approval of the NDA. In
addition, pralatrexate is being evaluated in patients with
non-small cell lung cancer, bladder cancer and a range of lymphoma
sub-types. Allos retains exclusive worldwide rights to pralatrexate
for all indications. The Company is headquartered in Westminster,
Colo. For more information about Allos, visit www.allos.com.
Safe Harbor Statement
The 2009 second quarter results press release and conference
call will contain forward-looking statements that involve
significant risks and uncertainties, including those contained in
the "Risk Factors" section of the company's Form 10-Q for the
quarter ended March 31, 2009 and in the company's other periodic
reports and filings with the Securities and Exchange Commission.
Allos is providing the information contained in the press release
and conference call as of the date of the release and does not
undertake any obligation to update any forward-looking statements
as a result of new information, future events or otherwise. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in the press release or the
conference call. No forward-looking statement can be guaranteed and
actual events and results may differ materially from those
projected.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Allos Therapeutics, Inc.